Phosphatase-1-inhibitor-1 in physiological and pathological {beta}-adrenoceptor signaling.
Standard
Phosphatase-1-inhibitor-1 in physiological and pathological {beta}-adrenoceptor signaling. / Wittköpper, Katrin; Dobrev, Dobromir; Eschenhagen, Thomas; El-Armouche, Ali.
in: CARDIOVASC RES, Jahrgang 91, Nr. 3, 3, 2011, S. 392-401.Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - Phosphatase-1-inhibitor-1 in physiological and pathological {beta}-adrenoceptor signaling.
AU - Wittköpper, Katrin
AU - Dobrev, Dobromir
AU - Eschenhagen, Thomas
AU - El-Armouche, Ali
PY - 2011
Y1 - 2011
N2 - Control of protein phosphorylation/dephosphorylation events occurs through regulation of protein kinases and phosphatases. The phosphatase type 1 (PP-1) compromises the main activity of Ser/Thr protein phosphatases in the heart. Inhibitor-1 (I-1) was the first endogenous molecule found to specifically inhibit PP-1. Notably, I-1 is activated by cAMP-dependent protein kinase A (PKA) and the subsequent prevention of target-dephosphorylation by PP-1 provides distal amplification of -adrenoceptor ( -AR) signaling. I-1 was found to be downregulated and hypophosphorylated in human and experimental heart failure but hyperactive in human atrial fibrillation, implicating I-1 in the pathogenesis of heart failure and arrhythmias. Consequently, the therapeutic potential of I-1 in heart failure and arrhythmias has been recently addressed by the generation and analysis of several I-1 genetic mouse models. This review summarizes and discusses these data, highlights partially controversial issues on whether I-1 should be therapeutically reinforced or inhibited and suggests future directions to better understand the functional role of I-1 in physiological and pathological -AR signaling.
AB - Control of protein phosphorylation/dephosphorylation events occurs through regulation of protein kinases and phosphatases. The phosphatase type 1 (PP-1) compromises the main activity of Ser/Thr protein phosphatases in the heart. Inhibitor-1 (I-1) was the first endogenous molecule found to specifically inhibit PP-1. Notably, I-1 is activated by cAMP-dependent protein kinase A (PKA) and the subsequent prevention of target-dephosphorylation by PP-1 provides distal amplification of -adrenoceptor ( -AR) signaling. I-1 was found to be downregulated and hypophosphorylated in human and experimental heart failure but hyperactive in human atrial fibrillation, implicating I-1 in the pathogenesis of heart failure and arrhythmias. Consequently, the therapeutic potential of I-1 in heart failure and arrhythmias has been recently addressed by the generation and analysis of several I-1 genetic mouse models. This review summarizes and discusses these data, highlights partially controversial issues on whether I-1 should be therapeutically reinforced or inhibited and suggests future directions to better understand the functional role of I-1 in physiological and pathological -AR signaling.
M3 - SCORING: Zeitschriftenaufsatz
VL - 91
SP - 392
EP - 401
JO - CARDIOVASC RES
JF - CARDIOVASC RES
SN - 0008-6363
IS - 3
M1 - 3
ER -